Research programme: antibody therapies - Hanwha Chemical

Drug Profile

Research programme: antibody therapies - Hanwha Chemical

Alternative Names: HD 101; HD 104; HD 105; HD 106

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Hanwha Chemical
  • Class Antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Rheumatoid arthritis
  • No development reported Cancer; Multiple sclerosis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in South Korea (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for research development in Multiple-sclerosis in South Korea
  • 01 Jun 2015 Early research in Rheumatoid arthritis in South Korea (unspecified route) (Hanwha Biologics website, June 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top